Lisata Therapeutics, Inc. (LSTA) 股票分析

公司概述

Lisata Therapeutics, Inc. operates as a clinical-stage pharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies aimed at treating solid tumors and other complex diseases. The firm functions within the broader Healthcare sector and the specific Biotechnology industry, where companies are typically characterized by high capital expenditure requirements and significant regulatory hurdles before achieving commercialization. As of the latest available data, the company holds a market capitalization of $45.16 million, generating annual revenue of $170,000, and maintains a lean operational structure with 21 employees. These financial figures indicate that the company is a micro-cap entity with minimal current revenue generation relative to its valuation, suggesting it is still in an early-stage development phase where market capitalization primarily reflects potential future value rather than established earnings power.

财务健康

The company reports a trailing twelve-month revenue of $170,000, while recording a net income of -$16,586,000 and an EBITDA of -$18,063,000. The substantial gap between the negligible revenue of $170,000 and the massive net loss of -$16.586 million reveals an extremely high cost structure driven by research and development expenses inherent to clinical-stage biotechnology firms. Free cash flow stands at -$10,854,625, indicating that the company is burning cash at a rapid pace to fund its clinical trials and operational activities. Regarding profitability metrics, the gross margin is reported at 100.0%, which is typical for biotech firms that have not yet incurred significant cost of goods sold, while the operating margin is a negative 3079.0% and the profit margin is 0.0%, reflecting severe operational losses relative to the tiny revenue base. In terms of liquidity and leverage, the company holds $15.96 million in cash against $0 in debt, and the debt-to-equity ratio is listed as N/A due to the lack of equity base or debt, presenting a balance sheet that is technically unleveraged but cash-constrained. The current ratio is 5.76, which indicates a strong ability to meet short-term obligations given the absence of debt, although this metric does not account for the long-term runway required for drug development. Finally, the return on equity is -75.5% and the return on assets is -43.2%, metrics that reveal that management is currently consuming shareholder value and assets to fund the clinical pipeline rather than generating returns.

估值评估

Valuation multiples for the company present a unique profile typical of pre-revenue biotech firms, where the trailing P/E ratio is N/A and the forward P/E is listed as -7.58. The negative forward P/E implies that the market is pricing in future earnings potential that has not yet materialized, rather than valuing the company on current profitability. The price-to-book ratio stands at 2.97, suggesting that the market is currently assigning a premium of nearly three times the book value to the company's assets. Alternative valuation metrics show a price-to-sales ratio of 265.66 and an EV/EBITDA of -1.60, which suggests the market is placing extreme value on the company's intangible assets and clinical pipeline rather than its financial statements. The stock has traded between a 52-week low of $1.81 and a 52-week high of $5.07, meaning the current price sits at a level that reflects significant volatility within this trading range. The beta value is 1.11, indicating that the stock's price volatility is slightly higher than the broader market, as a beta greater than one suggests the stock will amplify market movements.

Growth & Income

The company's financial trajectory shows a revenue growth rate of -90.0% year-over-year, while earnings growth is listed as N/A due to the company's persistent losses. The negative revenue growth indicates a contraction in sales or a decline in the specific revenue streams currently active, which is a critical metric to monitor for a company attempting to transition from research to commercialization. Since the company has not generated positive earnings, there is no dividend yield or payout ratio to evaluate for sustainability, as the payout ratio is 0.0%. Consequently, the company does not distribute profits to shareholders but instead retains all available capital to reinvest into its clinical trials and therapeutic development programs. The overall growth and income profile for Lisata Therapeutics is defined by negative revenue momentum and a complete reliance on internal cash reserves and potential external financing to sustain operations without generating current income.